Envista Holdings (NVST) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Envista Holdings

NYSE•Healthcare•Medical Instruments & Supplies

$24.97+0.24(0.01%)Pre-market

Market Cap

$3.78B

P/E

39.8x

P/S

1.3x

P/B

1.2x

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

How this company scores

GoodMetricSide Score: 71/100

Strongest: Growth (23/25); weakest: Profitability (14/25).

Profitability14/25

Growth23/25

Balance Sheet & Red Flags18/25

Cash & Earnings Quality16/25

Strengths

Rising earningsLow leverageCash-backed earningsConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 39.8x5y range 18.6x – 217.0x

Currently above its 14-quarter median.

P/S · 1.3x5y range 1.1x – 3.2x

Currently near its 20-quarter median.

P/B · 1.2x5y range 0.9x – 2.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $3.78B

Metrics at a Glance

as of July 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.86B
Q. Revenue: $730.50M
TTM EBITDA: $388.90M
TTM Op. Income: $273.60M
Q. Op. Income: $80.30M
TTM Net Income: $95.00M
Q. Net Income: $53.70M
EPS: $0.33
Shares Out.: $161.90M

$2.86B in TTM revenue grew 11.9% YoY, reaching $730.50M last quarter. TTM EBITDA of $388.90M and TTM operating income of $273.60M show growth is flowing through to the bottom line. TTM net income of $95.00M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 55.7%
EBITDA Margin: 14.8%
Op. Margin: 11.0%
Net Margin: 7.4%

Op. margin of 11.0% is up 4.2% YoY — cost efficiency is improving. Net margin at 7.4% and gross margin of 55.7% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 62% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 39.8x
P/S Ratio: 1.3x
P/B Ratio: 1.2x

At 39.8x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 1.3x and P/B of 1.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 5 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $5.60B
Cash: $1.13B
Long-Term Debt: $1.44B
Book Value: $3.08B
D/E Ratio: 0.5
Debt/EBITDA: 13.3

With $5.60B in assets and $1.44B in long-term debt, D/E is 0.5and book value is $3.08B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 1% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $119.20M
TTM Free Cash Flow: $248.10M
FCF Margin: 8.7%
FCF / Net Income: 2.6

TTM FCF of $248.10M on $119.20M in operating cash flow. The FCF / Net Income ratio of 2.6x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 4% — an improving trend.